Tolerance of pelvic organs to radiation treatment for carcinoma of cervix

Clinical Oncology

Volumn 15, Issue 5, 2003, Pages 240-247

  Sundar, S ^a   Symonds, Paul ^b   Deehan, C ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cervix carcinoma; Chemotherapy; Complications; Radiation tolerance; Radiotherapy

Indexed keywords

BEAM THERAPY; BLADDER INJURY; BRACHYTHERAPY; CANCER RADIOTHERAPY; DOSIMETRY; HUMAN; INTESTINE INJURY; PELVIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOBIOLOGY; RADIOSENSITIVITY; RECTUM INJURY; REVIEW; UTERINE CERVIX CARCINOMA; UTERUS DISEASE; VAGINA DISEASE;

EID: 0041629443     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(02)00455-7     Document Type: Review

References (103)

1. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-540.
2. Denton AS, Bond SJ, Matthews S, et al. National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993. Clin Oncol 2000;12:347-353.
3. Eifel PJ, Levenback C, Wharton JT, et al. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995;32:1289-1300.
4. Chatani M, Matayoshi Y, Masaki N, et al. A prospective randomized study concerning the point A dose in high-dose rate intracavitary therapy for carcinoma of the uterine cervix. The final results. Strahlenther Onkol 1994;170:636-642.
5. Barillot I, Horiot JC, Maingon P, et al. Impact on treatment outcome and late effects of customized treatment planning in cervix carcinomas: baseline results to compare new strategies. Int J Radiat Oncol Biol Phys 2000;48:189-200.
6. Komaki R, Brickner TJ, Hanlon AL, et al. Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978, and 1983: patterns of care study (PCS). Int J Radiat Oncol Biol Phys 1995;31:973-982.
7. Taylor PM, Johnson RJ, Eddleston B, et al. Radiological changes in the gastrointestinal and genitourinary tract following radiotherapy for carcinoma of the cervix. Clin Radiol 1990;41:165-169.
8. Perez CA. Uterine Cervix. In: Perez C, Brady L, eds. Principles and Practice of Radiation Oncology. Philadelphia: Lippincott-Raven Publishers, 1997:1733-1834.
9. Lanciano RM, Martz K, Montana GS, et al. Influence of age, prior abdominal surgery, fraction size, and dose on complications after radiation therapy for squamous cell cancer of the uterine cervix. A patterns of care study. Cancer 1992;69:2124-2130.
10. Montz FJ, Holschneider CH, Solh S, et al. Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings. Gynecol Oncol 1994;53:114-120.
11. Letschert JG, Lebesque JV, de Boer RW, et al. Dose-volume correlation in radiation-related late small-bowel complications: a clinical study. Radiother Oncol 1990;18:307-320.
12. Roeske JC, Mundt AJ, Halpern H, et al. Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix: a dosimetric analysis. Int J Radiat Oncol Biol Phys 1997; 37:351-358.
13. Eifel PJ, Jhingran A, Bodurka DC, et al. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol 2002;20:3651-3657.
14. Rubin P, Constine L, Williams J. Late effects of cancer treatment: radiation and drug toxicity. In: Perez C, Brady L, eds. Principles and Practice of Radiation Oncology. Philadelphia: Lippincott-Raven Publishers, 1997:155-211.
15. Vigliotti AP, Wen BC, Hussey DH, et al. Extended field irradiation for carcinoma of the uterine cervix with positive periaortic nodes. Int J Radiat Oncol Biol Phys 1992;23:501-509.
16. Perez CA, Grigsby PW, Lockett MA, et al. Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. Int J Radiat Oncol Biol Phys 1999;44:855-866.
17. Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA 1995;274:387-393.
18. Roeske JC, Lujan A, Rotmensch J, et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2000;48:1613-1621.
19. Parkin DE, Davis JA, Symonds RP. Long-term bladder symptomatology following radiotherapy for cervical carcinoma. Radiother Oncol 1987;9:195-199.
20. Parkin DE, Davis JA, Symonds RP. Urodynamic findings following radiotherapy for cervical carcinoma. Br J Urol 1988;61:213-217.
21. Levenback C, Eifel PJ, Burke TW, et al. Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol 1994;55:206-210.
22. Perez CA, Breaux S, Bedwinek JM, et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications. Cancer 1984;54:235-246.
23. Li A, Sun J, Chao H. Late bladder complications following radiotherapy of carcinoma of the uterine cervix. Zhonghua Fu Chan Ke Za Zhi 1995:30:741-743.
24. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
25. Montana GS, Fowler WC. Carcinoma of the cervix: analysis of bladder and rectal radiation dose and complications. Int J Radiat Oncol Biol Phys 1989;16:95-100.
26. Yalman D, Arican A, Ozsaran Z, et al. Evaluation of morbidity after external radiotherapy and intracavitary brachytherapy in 771 patients with carcinoma of the uterine cervix or endometrium. Eur J Gynaecol Oncol 2002;23:58-62.
27. Ferrigno R, dos Santos Novaes PE, Pellizzon AC, et al. High-dose-rate brachytherapy in the treatment of uterine cervix cancer. Analysis of dose effectiveness and late complications. Int J Radiat Oncol Biol Phys 2001;50:1123-1135.
28. Lukka HR, Moore CJ, Hunter RD. The relationship between the bladder and the cervix in patients undergoing intracavitary therapy. Br J Radiol 1987;60:355-359.
29. Kuipers T, Visser AG. Technical aspects of bladder dosimetry in intracavitary irradiation of cervix carcinoma. Radiother Oncol 1986;7:7-12.
30. ICRU Report 38. Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology. Bethesda, MD, USA: International Commission on Radiation Units and Measurements, 1985.
31. Potter R, Van Limbergen E, Gerstner N, et al. Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy. Radiother Oncol 2001;58:11-18.
32. Orton CG, Wolf-Rosenblum S. Dose dependence of complication rates in cervix cancer radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:37-44.
33. Stryker JA, Bartholomew M, Velkley DE, et al. Bladder and rectal complications following radiotherapy for cervix cancer. Gynecol Oncol 1988:29:1-11.
34. Hunter RD, Wong F, Moore C, et al. Bladder base dosage in patients undergoing intracavitary therapy. Radiother Oncol 1986;7:189-197.
35. Sinistrero G, Sismondi P, Rumore A, et al. Analysis of complications of cervix carcinoma treated by radiotherapy using the Franco-Italian glossary. Radiother Oncol 1993;26:203-211.
36. Crook JM, Esche BA, Chaplain G, et al. Dose-volume analysis and the prevention of radiation sequelae in cervical cancer. Radiother Oncol 1987;8:321-332.
37. Barillot I, Horiot JC, Maingon P, et al. Maximum and mean bladder dose defined from ultrasonography. Comparison with the ICRU reference in gynaecological brachytherapy. Radiother Oncol 1994;30:231-238.
38. Palmer J, Pearcey R, Lukka H. The use of CT for selectron patients. Med Dosim 1990;15:193-197.
39. Gebara WJ, Weeks KJ, Hahn CA, et al. Computed axial tomography tandem and ovoids (CATTO) dosimetry: three-dimensional assessment of bladder and rectal doses. Radiat Oncol Investig 1998;6:268-275.
40. Kapp KS, Stuecklschweiger GF, Kapp DS, et al. Dosimetry of intracavitary placements for uterine and cervical carcinoma: results of orthogonal film, TLD, and CT-assisted techniques. Radiother Oncol 1992;24:137-146.
41. Tan LT, Warren J, Freestone G, et al. Bladder dose estimation during intracavitary brachytherapy for carcinoma of the cervix using a single line source system. Br J Radiol 1996;69:953-962.
42. Chen GD, Lin LY, Wang PH, et al. Urinary tract dysfunction after radical hysterectomy for cervical cancer. Gynecol Oncol 2002;85:292-297.
43. Farquharson DI, Shingleton HM, Soong SJ, et al. The adverse effects of cervical cancer treatment on bladder function. Gynecol Oncol 1987;27:15-23.
44. Esche BA, Crook JM, Horiot JC. Dosimetric methods in the optimization of radiotherapy for carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1987;13:1183-1192.
45. Hunter R. Carcinoma of cervix. In: Peckham MJ, Pinedo HM, Veronesi U, eds. Oxford Textbook of Oncology, 1st edn. Oxford: Oxford University Press, 1995;2:1324-1349.
46. Leborgne F, Fowler JF, Leborgne JH, et al. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix. Radiat Oncol Investig 1997;5:289-299.
47. Clark BG, Souhami L, Roman TN, et al. The prediction of late rectal complications in patients treated with high dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997;38:989-993.
48. Sherrah-Davies E. Morbidity following low-dose-rate selectron therapy for cervical cancer. Clin Radiol 1985;36:131-139.
49. Haie-Meder C, Kramar A, Lambin P, et al. Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. Int J Radiat Oncol Biol Phys 1994;29:953-960.
50. Lambin P, Gerbaulet A, Kramar A, et al. A comparison of early effects with two dose rates in brachytherapy of cervix carcinoma in a prospective randomised trial. Eur J Cancer 1994;3:312-320.
51. Patel FD, Sharma SC, Negi PS, et al. Low dose rate vs high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys 1994;28:335-341.
52. Teshima T, Inoue T, Ikeda H, et al. High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. Cancer 1993;72:2409-2414.
53. Deore SM, Shrivastava SK, Viswanathan PS, et al. The severity of late rectal and recto-sigmoid complications related to fraction size in irradiation treatment of carcinoma cervix stage III B. Strahlenther Onkol 1991;167:638-642.
54. MacLeod C, Bernshaw D, Leung S, et al. Accelerated hyper-fractionated radiotherapy for locally advanced cervix cancer. Int J Radiat Oncol Biol Phys 1999;44:519-524.
55. Kavanagh BD, Gieschen HL, Schmidt-Ullrich RK, et al. A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 1997;38:561-568.
56. Strockbine ME, Hancock JE, Fletcher GH. Complications in 831 patients with squamous cell carcinoma of the intact uterine cervix treated with 3000 rads or more whole pelvis irradiation. Am J Roentgenol Radium Ther Nucl Med 1970;108:293-304.
57. Hamberger AD, Unal A, Gershenson DM, et al. Analysis of the severe complications of irradiation of carcinoma of the cervix: whole pelvis irradiation and intracavitary radium. Int J Radiat Oncol Biol Phys 1983;9:367-371.
58. Chen SW, Liang JA, Yang SN, et al. The prediction of late rectal complications following the treatment of uterine cervical cancer by high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:955-961.
59. Christie DR, Bull CA, Gebski V, et al. Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer. Radiother Oncol 1995;37:181-189.
60. Rakovitch E, Fyles AW, Pintilie M, et al. Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997;38:979-987.
61. Wang CJ, Leung SW, Chen HC, et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: evidence suggestive of consequential late effect (CQLE). Int J Radiat Oncol Biol Phys 1998;40:85-91.
62. Bourne RG, Kearsley JH, Grove WD, et al. The relationship between early and late gastrointestinal complications of radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1983;9:1445-1450.
63. Sutton M. Gynaecological radiotherapy. In: Hope-Stone H, ed. Radiotherapy in Clinical Practice. London: Butterworth & Co (Publishers) Ltd, 1986:203-237.
64. Corner GA, Skinner DL, Watson ER. Selectron: rectal dose-rate measurements and modified applicators. Clin Radiol 1982;33:477-480.
65. Serkies K, Badzio A, Jereczek-Fossa B, et al. Rectal doses in intracavitary brachytherapy of gynecological malignancies: comparison of two dosimetric methods. Radiother Oncol 2001;58:37-41.
66. Pourquier H, Dubois JB, Delard R. Cancer of the uterine cervix: dosimetric guidelines for prevention of late rectal and rectosigmoid complications as a result of radiotherapeutic treatment. Int J Radiat Oncol Biol Phys 1982;8:1887-1895.
67. Deshpande DD, Shrivastav SK, Pradhan AS, et al. Dosimetry of intracavitary applications in carcinoma of the cervix: rectal dose analysis. Radiother Oncol 1997;42:163-166.
68. van den Bergh F, Meertens H, Moonen L, et al. The use of a transverse CT image for the estimation of the dose given to the rectum in intracavitary brachytherapy for carcinoma of the cervix. Radiother Oncol 1998;47:85-90.
69. Orton CG. HDR: forget not 'time' and 'distance'. Int J Radiat Oncol Biol Phys 1991;20:1131-1132.
70. Potter R, Knocke TH, Fellner C, et al. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations. Cancer Radiother 2000; 4:159-172.
71. Petereit DG, Pearcey R. Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys 1999;43:359-366.
72. Paris KJ, Spanos WJ Jr, Day TG Jr, et al. Incidence of complications with mini vaginal culpostats in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1991;21:911-917.
73. Yorke ED, Schell MC, Gaskill JW, et al. Using measured dose distribution data of the Fletcher-Suit-Delclos colpostat in brachytherapy treatment planning. Int J Radiat Oncol Biol Phys 1987; 13:1413-1419.
74. Tan LT, Jones B, Shaw JE. Radical radiotherapy for carcinoma of the uterine cervix using external beam radiotherapy and a single line source brachytherapy technique: the Clatterbridge technique. Br J Radiol 1997;70:1252-1258.
75. Hunter R, Davidson S. Low dose-rate brachytherapy for treating cervix cancer: changing dose rate. In: Joslin C, Flynn A, Hall E, eds. Principles and Practice of Brachytherapy (using after-loading systems). London: Arnold, 2001:343-353.
76. Nag S, Gupta N. A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 2000; 46:507-513.
77. Patel FD, Negi PS, Sharma SC, et al. Dose rate correction in medium dose rate brachytherapy for carcinoma cervix. Radiother Oncol 1998;49:317-323.
78. Orton CG, Seyedsadr M, Somnay A. Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys 1991; 21:1425-1434.
79. Huang EY, Lin H, Hsu HC, et al. High external parametrial dose can increase the probability of radiation proctitis in patients with uterine cervix cancer. Gynecol Oncol 2000;79:406-410.
80. Gerstner N, Wachter S, Knocke TH, et al. The benefit of Beam's eye view based 3D treatment planning for cervical cancer. Radiother Oncol 1999;51:71-78.
81. Portelance L, Chao KS, Grigsby PW, et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 2001;51:261-266.
82. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161.
83. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143.
84. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
85. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:781-786.
86. Sismondi P, Sinistrero G, Zola P, et al. Complications of uterine cervix carcinoma treatments: the problem of a uniform classification. Radiother Oncol 1989;14:9-17.
87. Watkins-Bruner D, Scott C, Lawton C, et al. RTOG's first quality of life study-RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:901-906.
88. Pedersen D, Bentzen SM, Overgaard J. Early and late radiotherapeutic morbidity in 442 consecutive patients with locally advanced carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994;29:941-952.
89. Bentzen SM, Vaeth M, Pedersen DE, et al. Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now! Int J Radiat Oncol Biol Phys 1995;32:1531-1534.
90. Visser AG, Symonds RP. Dose and volume specification for reporting gynaecological brachytherapy: time for a change. Radiother Oncol 2001;58:1-4.
91. Deehan C. Brachytherapy into the new millennium. In: Sharp P, Perkins A, eds. Physics and engineering in medicine in the new millenium. London: Institute of Physics and Engineering in Medicine, 2000:130-141.
92. Chu JC, Ni B, Kriz R, et al. Applications of simulator computed tomography number for photon dose calculations during radiotherapy treatment planning. Radiother Oncol 2000; 55:65-73.
93. Parker RP, Hobday PA, Cassell KJ. The direct use of CT numbers in radiotherapy dosage calculations for inhomogeneous media. Phys Med Biol 1979;24:802-809.
94. Schneider U, Pedroni E, Lomax A. The calibration of CT Hounsfield units for radiotherapy treatment planning. Phys Med Biol 1996;41:111-124.
95. Schoeppel SL, Fraass BA, Hopkins MP, et al. A CT-compatible version of the Fletcher system intracavitary applicator: clinical application and 3-dimensional treatment planning. Int J Radiat Oncol Biol Phys 1989;17:1103-1109.
96. Schoeppel SL, Ellis JH, LaVigne ML, et al. Magnetic resonance imaging during intracavitary gynecologic brachytherapy. Int J Radiat Oncol Biol Phys 1992;23:169-174.
97. Tardivon AA, Kinkel K, Lartigau E, et al. MR imaging during intracavitary brachytherapy of vaginal and cervical cancer: preliminary results. Radiographics 1996;16:1363-1370.
98. Khoo VS, Dearnaley DP, Finnigan DJ, et al. Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Radiother Oncol 1997;42:1-15.
99. Mutic S, Dempsey JF, Bosch WR, et al. Multimodality image registration quality assurance for conformal three-dimensional treatment planning. Int J Radiat Oncol Biol Phys 2001;51:255-260.
100. Mongioj V, Brusa A, Loi G, et al. Accuracy evaluation of fusion of CT, MR, and spect images using commercially available software packages (SRS PLATO and IFS). Int J Radiat Oncol Biol Phys 1999;43:227-234.
101. Chen L, Li J, Mah D, et al. Monte Carlo verification of MR-based treatment planning for intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:329.
102. Lee SW, Suh CO, Chung EJ, et al. Dose optimization of fractionated external radiation and high-dose-rate intracavitary brachytherapy for FIGO stage IB uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 2002;52:1338-1344.
103. Ogino I, Kitamura T, Okamoto N, et al. Late rectal complication following high dose rate intracavitary brachytherapy in cancer of the cervix. Int J Radiat Oncol Biol Phys 1995;31:725-734.